Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab

Cornea - United States
doi 10.1097/ico.0000000000000627
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Secukinumab: First IL-17A Antagonist for Plaque Psoriasis

Pharmacy Today
2015English

IL-17A Softens the Skin: Antifibrotic Properties of IL-17A in Systemic Sclerosis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2020English

Opioid Exacerbation of Gram-Positive Sepsis, Induced by Gut Microbial Modulation, Is Rescued by IL-17A Neutralization

Scientific Reports
Multidisciplinary
2015English

The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond

Expert Review of Clinical Immunology
AllergyImmunology
2019English

Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus

Frontiers in Immunology
AllergyImmunology
2018English

Potentiation of IL-19 Expression in Airway Epithelia by IL-17A and IL-4/IL-13: Important Implications in Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2008English

Inhibition of Keratinocyte Differentiation by the Synergistic Effect of IL-17A, IL-22, IL-1α, TNFα and Oncostatin M

PLoS ONE
Multidisciplinary
2014English

The Impact of Conjunctivochalasis on Dry Eye Symptoms and Signs

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2015English

Vagotomy Blocks the Induction of Interleukin-1β (IL-1β) mRNA in the Brain of Rats in Response to Systemic IL-1β

Journal of Neuroscience
Neuroscience
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy